IGC Pharma, Inc. (IGC) financial statements and ratios from SEC XBRL: revenue $869000.00 (TTM), net margin -477.1%, revenue growth -19.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $869000.00 |
| Net Margin | -477.1% |
| Revenue Growth (YoY) | -19.2% |
| EPS Growth (YoY) | 50.0% |
| FCF Growth (YoY) | 82.3% |
| Price / Book | 5.14 |
| Price / Sales | 28.60 |
| FCF Yield | -27.8% |
| Altman Z-Score | -12.70 (distress) |
| Piotroski F-Score | 2/9 |
| Sector P/E (Healthcare) | 21.7 |
IGC overview · IGC earnings · IGC KPIs · IGC investor relations · IGC ownership · IGC peers · IGC filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.